

OneSource reports Q2FY26 performance with revenue growth of 12% and margin expansion of 506 bps YoY

Q2FY26 Performance Highlights

- Revenues at ₹3,758 million, up 12% YoY
- EBITDA grew 37% YoY to ₹1,065 million
- EBITDA margin of 28%, an expansion of ~506 bps YoY
- Adjusted PAT stood at ₹449 million with adjusted EPS of ₹3.9

Kochi, India, November 12, 2025 - OneSource Speciality Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended September 30, 2025 (Q2FY26).

Financial Highlights (In ₹ million)

Particulars	Q2FY26	QoQ%	YoY%	H1FY26	YoY%
Revenues	3,758	+15%	+12%	7,030	+12%
EBITDA	1,065	+20%	+37%	1,950	+37%
EBITDA %	28%	~130 bps	~ 506 bps	28%	~ 504 bps
Adjusted PAT ¹	449	+21%	Loss to profit	820	Loss to profit ²
Adjusted EPS (₹) ¹	3.9	+21%	-	7.2	-

1. Adjusted PAT and Adjusted EPS excludes exceptional items (Q2FY26: Nil, Q1FY26: ₹29m, Q2FY25: ₹58m) and scheme related intangible amortisation (FY26: ₹344m for each quarter, Q2FY25: ₹357m)
2. Excludes one-time tax asset recognised (Q1FY25: ₹411m) as a results of the scheme of arrangement.

The recently announced proposed acquisition of Poland and Brooks delivered a strong first half with a combined revenue of \$29 million and EBITDA of \$11 million, translating into healthy margins of 38%.

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to \$500m+.”

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,400 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

<u>Institutional Investors</u> Anurag Bhagania CFO Tejaswani Fotedar +91 9004331391 Email: investor-relations@onesourcecdmo.com	<u>Corporate Communication</u> Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com Abhilash Mukherjee: +91 89044 28907 Email: abhilash,mukherjee@onesourcecdmo.com Harsh Sheth: +91 9870631557 Email: harsh.sheth@mslgroup.com
--	---